NFL BIOSCIENCES : Decision of aokay of deliverance of his patent in China
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announcement have received the consent of the Chinese National Intellectual Property Administration (CNIPA), for delivery of his patent (Chinese Application No.201780033409.5 ) portant on NFL-101, Botanical drug candidate composed of natural proteins extracted from tobacco leaves, nicotine-free, and primarily destined smoking cessation. This patent protectsout linnovation behind NFL-101 until 2036 in China.
NFL Biosciences has adopted a knowledge management and protection strategy that has led it to file two families of patents granting it exclusivity for its drug candidate NFL-101. This product patent, originally filed and approved in France, relates to an “aqueous extract of tobacco leaf and its use for the treatment of addiction”. The innovation on which NFL-101 is based is thus protected until 2036 in France, the United States and therefore soon in China. National registration applications are also under review in the following regions and countries: Japan, Canada, South Korea, Australia, Brazil, India, Indonesia, Israel, Mexico, Philippines, Eurasia, Saudi Arabia, United Arab Emirates , Nigeria.
China is the country with the largest number of smokers, with over 300 million, and where about 50% of the male population are smokers. If nothing is done, deaths from smoking-related cancers are expected to increase by 44% among men between 2020 and 2040, which would represent an excess mortality of 8.6 million deaths in 20 years.1. The reduction of smoking is a national issue, it is integrated into the heart of the “Healthy China” initiative which aims to improve the health of the Chinese population and which has the particular objective of reducing the overall smoking rate to 20% of here 2030.
« Nearly one in three cigarettes smoked in the world is smoked in China. Having a product patent gives us a protection strong to roll out our strategy over the next few years. This patent strengthens the protection of the innovation on which our drug candidate NFL-101 in China, a country that is part of the markets keys ciblIt’ss in the global approach deployed by NFL Biosciences. He was very important for us to hold solid intellectual property in this high-potential market says Bruno Lafont, Deputy CEO and co-founder of NFL Biosciences.
About NFL Biosciences
NFL Biosciences is a biopharmaceutical company based in the Montpellier region that develops botanical drug candidates for the treatment of addictions. NFL Biosciences aims to bring new therapeutic, natural, safer and more effective solutions to the entire world population, without forgetting countries with low or middle income levels. Its most advanced product, called NFL-101, is a standardized, nicotine-free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who wish to quit a natural, safe, simplified and personalized administration alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders.
NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). The company is qualified as an “Innovative Company” eligible for FCPI investment. More information on www.nflbiosciences.com
Bruno Lafont – firstname.lastname@example.org – 04 11 93 76 67 Calyptus Agency – email@example.com – 01 53 65 68 68
1 “Smoking-related cancer death among men and women in an ageing society (China 2020–2040): a population-based modelling study”Sept. 2021 : https://tobaccocontrol.bmj.com/content/early/2021/09/01/tobaccocontrol-2020-056444